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Abstract
Background and Objectives The effectiveness and toler-
ability of tapentadol extended release (ER), a centrally
acting analgesic with l-opioid receptor agonist and nor-
epinephrine (noradrenaline) reuptake inhibitor activities,
have been demonstrated in patients with chronic pain,
including those switching directly from prior opioid ther-
apy. The objective of the current study was to evaluate the
effectiveness and safety of conversion to oral tapentadol
ER (50–250 mg twice daily) from previous around-the-
clock strong opioid therapy in patients with moderate to
severe, chronic malignant tumor–related cancer pain that
was well-controlled.
Methods This randomized, open-label, phase III study,
which was conducted in Japan, included a 1- to 2-week
screening period (on previous opioid) and an 8-week, open-
label treatment period. Eligible patients, who were taking a
strong opioid analgesic and had a mean pain intensity score
\4 during the 3 days prior to randomization (adequate
pain control on previous strong opioid), were randomized
(1:1) to receive twice-daily treatment with tapentadol ER
(100–500 mg/day) or morphine sustained release (SR;
20–140 mg/day; reference for assay sensitivity). Initial
doses were estimated based on the conversion ratio of
tapentadol ER:oxycodone:morphine:fentanyl = 10:2:3:0.03.
The primary effectiveness endpoint was the proportion of
patients who maintained pain control [change from baseline
in mean pain intensity (11-point numerical rating scale) less
than ?1.5 for 3 consecutive days and no more than two
doses of rescue medication per day for 3 consecutive days)
during the first week of open-label treatment.
Results In the tapentadol ER group (n = 50), 84.0 % of
patients (42/50; 95 % CI, 70.89–92.83) maintained pain
control during Week 1. On the Patient Global Impression
of Change, 2.1 % (1/48), 2.1 % (1/48), 22.9 % (11/48), and
50.0 % (24/48) of patients in the tapentadol ER group
reported that their overall condition was ‘‘very much
improved,’’ ‘‘much improved,’’ ‘‘minimally improved,’’
and ‘‘not changed,’’ respectively, at Week 1 compared with
0 %, 10.7 % (3/28), 28.6 % (8/28), and 53.6 % (15/28)
reporting these ratings at Week 8. The sensitivity of
effectiveness analyses was validated based on results using
morphine SR; 98.0 % (49/50; 95 % CI, 89.35–99.95) of
patients in the morphine SR group maintained pain control
after 1 week of treatment. The overall safety profile was
similar to that demonstrated in previous studies; tapentadol
ER was associated with a lower incidence of gastrointes-
tinal treatment-emergent adverse events than morphine SR
[38.0 % (19/50) vs. 54.0 % (27/50)], including constipa-
tion [12.0 % (6/50) vs. 20.0 % (10/50)] and vomiting
[6.0 % (3/50) vs. 26.0 % (13/50)].
Conclusions Overall, results indicate that conversion
from previous strong opioids to tapentadol ER (50–250 mg
twice daily) was successful and resulted in safe and
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effective pain control with improved gastrointestinal tol-
erability versus morphine SR in patients with moderate to
severe cancer-related pain that was well-controlled on their
previous opioid.
Key Points
Patients with moderate to severe cancer-related pain
that was well-controlled on their previous opioid
analgesic could be safely converted to tapentadol
extended release (ER; 100–500 mg/day) with no loss
of pain control.
The majority of patients maintained pain control
within 1 week of conversion, indicating successful
direct conversion from prior opioid therapy to
tapentadol ER.
Tapentadol ER was associated with a better
gastrointestinal tolerability profile than morphine
sustained release (20–140 mg/day).
1 Introduction
World Health Organization (WHO) Step III opioid anal-
gesics (e.g., morphine) are often used for moderate to
severe cancer pain management [1–3]. The level of pain
relief achieved with opioid analgesics varies from patient
to patient [1], and many patients (approximately 10–30 %)
with cancer-related pain do not achieve adequate analgesia
with opioids [4]. In addition, side effects are common in
patients receiving long-term opioid treatment for chronic
pain [1]. Gastrointestinal side effects (e.g., constipation,
nausea, and vomiting) are particularly burdensome for
patients with cancer-related pain [2, 4]. Opioids induce
nausea, vomiting, and constipation in a high percentage of
patients taking opioid analgesics for cancer pain manage-
ment [5], and may exacerbate gastrointestinal symptoms
associated with the underlying disease or treatment. Opioid
switching is a proven approach for reducing intolerable
side effects that has also been shown to be effective at
improving analgesia for more than 50 % of patients with a
poor response to an initial opioid analgesic [6]. The Japa-
nese Society of Palliative Medicine recommends switching
the type of opioid used in patients with pain that is inad-
equately controlled or who experience intolerable side
effects (particularly nausea and vomiting) when taking a
particular opioid [7]. Improvements in pain intensity and
tolerability have been observed following rotation from
one opioid analgesic to another in multiple studies in
Japanese patients with cancer pain [8–10].
Tapentadol is a centrally acting analgesic with two
mechanisms of action: l-opioid receptor agonism and
norepinephrine (noradrenaline) reuptake inhibition [11, 12].
The gastrointestinal tolerability of tapentadol extended
release (ER) has been shown to be better than that of
equianalgesic doses of oxycodone controlled release (CR)
and morphine CR [13–17]. The effectiveness and safety of
tapentadol ER for the management of moderate to severe,
chronic tumor–related pain have been demonstrated in
phase III clinical studies [16, 18] and in exploratory [19]
and non-interventional [20] studies. In a phase III study in
patients with moderate to severe, chronic tumor–related
pain, tapentadol ER (100–250 mg twice daily) was shown
to provide non-inferior effectiveness to that of morphine
sulfate CR (40–100 mg twice daily) [16]. In a separate
phase III study in opioid-naive Japanese patients experi-
encing cancer pain, the analgesic effectiveness of tapent-
adol ER (25–200 mg twice daily) was shown to be non-
inferior to that of oxycodone HCl CR (5–40 mg twice daily)
[18]. Given its improved tolerability relative to opioid
analgesics [13–16], tapentadol ER could be considered as a
first option for patients who need opioid treatment to control
their pain. For patients who are taking another strong opioid
analgesic and experience intolerable opioid-induced side
effects, it may be necessary to switch directly from the prior
opioid to tapentadol ER to relieve those side effects.
In this 8-week, randomized, open-label phase III study
(ClinicalTrials.gov identifier: NCT01309386) conducted in
Japan, the effectiveness of tapentadol ER (50–250 mg
twice daily) in safely converting patients from previous
around-the-clock strong opioid therapy without loss of
previous pain control was evaluated in patients with
moderate to severe, chronic malignant tumor–related can-
cer pain that had been controlled by prior opioid therapy.
Morphine sustained release (SR) was included as a refer-
ence for assay sensitivity in the current study, not as a
direct comparator for effectiveness evaluations.
2 Patients and Methods
This study was conducted in accordance with the principles
of the Declaration of Helsinki, Good Clinical Practice
guidelines, and applicable regulatory requirements. The
study protocol and amendments were reviewed and
approved by Institutional Review Boards. Prior to study
enrolment, all patients or their legally acceptable repre-
sentatives provided their written consent to participate in
the study after being provided with information regarding
the nature and purpose of the study, participation/termi-
nation conditions, and the risks and benefits of treatment.
This study was a registration trial in Japan and was
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requested by the Japanese Pharmaceuticals and Medical
Devices Agency.
2.1 Patient Population
This study included men and women who were at least
20 years of age, had been diagnosed with cancer, and were
receiving around-the-clock opioid therapy for moderate to
severe, chronic malignant tumor–related cancer pain using
one of the following: oral morphine SR (B120 mg/day),
oral oxycodone HCl CR (15–80 mg/day), or transdermal
fentanyl (Durotep MT Patch, B8.4 mg/patch; Fentos
Tape, B4 mg/tape; OneDuro Patch, B3.4 mg/patch).
During the 3 days prior to randomization, opioid doses
must have been stable and the mean 24-h pain intensity
score must have been \4 on an 11-point numerical rating
scale (NRS) [0 = ‘‘no pain’’ to 10 = ‘‘pain as bad as you
can imagine’’]. Eligible patients were allowed to use oral
morphine immediate release (IR) or oxycodone IR as res-
cue medication for breakthrough pain. The dose per intake
of rescue medication must have been no more than one-
sixth of the total daily dose (TDD) of the around-the-clock
opioid analgesic, with conversion of the daily dose based
on the ratio of morphine:oxycodone:fentanyl of 3:2:0.03;
for patients who were taking morphine SR (20 mg/day) or
oxycodone HCl CR (15 mg/day), the minimal strengths of
rescue medication (morphine HCl IR 5 mg or oxycodone
HCl IR 2.5 mg) were used.
Exclusion criteria and prohibited and permitted medi-
cations are listed in the Electronic Supplementary Material.
2.2 Study Design
This randomized, open-label, parallel-arm, optimal dose-
titration, multicenter study included a 1- to 2-week
screening period and an 8-week open-label treatment per-
iod. During the study, patients were hospitalized or treated
as outpatients. Patients continued taking the same doses of
their previous around-the-clock daily opioid analgesics
throughout the screening period. Eligible patients with a
mean pain intensity score \4 during the 3 days prior to
randomization were then randomized (1:1) to receive
twice-daily treatment with tapentadol ER or morphine SR
(as a reference for assay sensitivity) for 8 weeks. Ran-
domization was stratified by prior opioid treatment to
ensure that the treatment assignment was balanced. Mor-
phine SR served as a reference for assay sensitivity, not as
an active comparator, to validate the results observed with
tapentadol ER. Starting doses of study drug were calculated
based on the previous opioid analgesic dose (Table 1).
Based on prior estimates of the equianalgesic ratio of ta-
pentadol ER to oxycodone CR (*5:1) [21, 22] and of the
equianalgesic ratio between oxycodone CR, morphine SR,
and a fentanyl transdermal system (2:3:0.03) [23–26],
conversion ratios between tapentadol ER and oxycodone,
morphine, and fentanyl for the initial dose were estimated
as tapentadol ER:oxycodone:morphine:fentanyl = 10:2:3:
0.03. In patients switching from a fentanyl transdermal
system, the system was to be removed at least 12 h before
administration of the first dose of study drug. Patients who
developed withdrawal symptoms after switching to study
treatment could receive oral oxycodone IR or oral mor-
phine IR (at an equivalent dose of one-fourth to one-tenth
the TDD of the previously used opioid) for up to 3 days
until symptoms disappeared. Patients were also permitted
to take oral oxycodone IR or oral morphine IR as rescue
medication for breakthrough pain throughout the study
(including the screening and open-label treatment periods);
the dose of rescue medication had to be no more than one-
sixth of the TDD of the around-the-clock opioid analgesics,
including study drug. Patients with a daily dose of ta-
pentadol ER \100 mg/day, morphine SR \20 mg/day, or
oxycodone HCl CR \15 mg/day were to use the minimal
strengths of rescue medication (morphine HCl IR 5 mg or
oxycodone HCl IR 2.5 mg).
After at least 2 days of treatment with the initial dose,
doses of study drug could be increased to a maximum of
tapentadol ER 500 mg/day or morphine SR 140 mg/day
based on the investigator’s judgment, which included
evaluating if a patient’s 24-h NRS score was C4 or had
worsened compared with the previous day or if rescue
medication for breakthrough pain was given C3 times per
day. For patients taking doses of tapentadol ER \200 mg/
day and morphine SR \60 mg/day, doses could be
increased in increments of tapentadol ER 50 mg/day and
morphine SR 10–20 mg/day, respectively. For patients
taking doses of tapentadol ER C200 mg/day and morphine
SR C60 mg/day, doses could be increased in increments of
tapentadol ER 100 mg/day or morphine SR 20–30 mg/day,
respectively. Doses could be reduced as needed during the
study for safety reasons [e.g., adverse events (AEs)] to a
minimum of tapentadol ER 50 mg/day or morphine SR
20 mg/day. Doses were titrated to each individual patient’s
optimal dose, balancing effectiveness and tolerability.
2.3 Study Endpoints and Assessments
Effectiveness in this study was evaluated as the ability to
convert patients from previous, around-the-clock strong
opioid therapy to tapentadol ER (50–250 mg twice daily)
without loss of previous pain control. Patients rated their
average pain intensity over the previous 24 h once daily on
an 11-point NRS throughout the study. The primary
effectiveness endpoint was defined as the proportion of
patients who maintained pain control during the first week
of the open-label treatment period. Pain control was
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defined as having a change from baseline in the mean 24-h
pain intensity score (11-point NRS) of less than ?1.5 and
using no more than two doses of rescue medication per day
for any 3 consecutive days during the first week. Patients
were enrolled in the study only if their pain was well-
controlled [i.e., pain intensity (NRS) score \4] on their
previous opioid therapy; thus, pain was considered to be
controlled on study treatment only if patients experienced
minimal changes in pain intensity after conversion from
prior therapy.
Secondary effectiveness endpoints included average
weekly pain intensity scores (11-point NRS), Patient Global
Impression of Change (PGIC) ratings, and rescue medication
use. The PGIC is a validated measure of global improvement
with treatment for chronic pain [27, 28]. For the PGIC,
patients completed the statement ‘‘Since the start of this
treatment, my cancer-related pain overall is,’’ using a 7-point
scale (1 = ‘‘very much improved’’ to 7 = ‘‘very much
worse’’). The PGIC was completed at Weeks 1, 2, 4, 6, and at
the end of study or early withdrawal. The total number of
days that patients took rescue medication, number of rescue
medication doses taken in a calendar day, and TDD of rescue
medication were evaluated for each patient.
Safety assessments included recorded AEs, clinical
laboratory parameters, vital signs, 12-lead electrocardio-
grams (ECGs), and physical examinations. A treatment-
emergent AE (TEAE) was defined as any AE that occurred
on or after the first intake of study drug or that started
before the first intake of study drug and worsened in
intensity during the active treatment period. Incidences of
TEAEs reported here include all TEAEs that occurred
during the 8-week treatment period, and incidences of
serious AEs reported here include all serious AEs that
occurred during the 8-week treatment period and any
spontaneously reported serious AEs within 7 days of the
end of treatment.
2.4 Statistical Analyses
Based on results from previous studies with tapentadol and
transdermal fentanyl [29], it was estimated that 49 patients
should be included in the tapentadol ER group, assuming
that the percentage of patients achieving pain control in
this study was 85 % and the lower limit of the 2-sided
95 % confidence interval (CI) was [75 % (-10 %).
Morphine SR was used to evaluate assay sensitivity in this
study, and the same number of patients were to be enrolled
to receive morphine SR treatment as in the tapentadol ER
group, bringing the total number of subjects to approxi-
mately 100. The estimated number of patients to be
enrolled by previous opioid treatment was as follows:
morphine SR, n = 20; oxycodone CR, n = 40; fentanyl
transdermal system, n = 40.
In this study, the safety population included all ran-
domized patients who received at least one dose of study
medication. The full analysis population, which was used
for all effectiveness analyses, included all randomized
patients who received at least one dose of study medication
and had post-baseline effectiveness data.
For baseline and demographic characteristics and study
drug dosing data, descriptive statistics were used to sum-
marize continuous variables, and frequency counts were
used to summarize categorical variables. Study drug dosing
information evaluated included the TDD of study drug,
modal (or most frequently used) dose, duration of treat-
ment, and the number of dose adjustments.
For the primary effectiveness analysis, the percentage
(with 95 % CI) of patients who maintained pain control
during the first week of treatment was calculated. Patients
who discontinued after \3 days of treatment or who did
not have any available 24-h pain intensity scores (11-point
NRS) for 3 consecutive days during the first week of
treatment were considered to have not maintained pain
Table 1 Starting daily dose of study drug based on dose of previous opioid treatment
Previous opioid dose (mg) Starting dose (mg)
Oxycodone CR Durotep MT Patcha Fentos Tapea OneDuro Patcha Morphine SR Tapentadol ER Morphine SRb
C15 to B20 2.1 (0.3 mg/day) 1 (0.3 mg/day) 0.84 (0.3 mg/day) C20 to B30 100 30
[20 to B30 – – – [30 to B40 150 40c
[30 to B40 4.2 (0.6 mg/day) 2 (0.6 mg/day) 1.7 (0.6 mg/day) [40 to B60 200 60
[40 to B60 6.3 (1.2 mg/day) 3 (1.2 mg/day) 2.54 (1.2 mg/day) [60 to B90 300 90
[60 to B80 8.4 (1.8 mg/day) 4 (1.8 mg/day) 3.4 (1.8 mg/day) [90 to B120 400 120
CR controlled release, ER extended release, SR sustained release, – indicates absence of doses converted
a Previous opioid dose (mg) of Durotep MT Patch, Fentos Tape, and OneDuro Patch indicates fentanyl content per patch or tape. Nominal
release rate (mg/day) of fentanyl is shown in parentheses
b Starting doses of morphine SR shown are for patients who were previously taking oxycodone CR, the Durotep MT Patch, Fentos Tape, or
the OneDuro Patch. Patients who were previously taking morphine SR continued on the same dose
c Although the dose calculated based on the equianalgesic ratio was 45 mg, a 40-mg dose was used because a 45-mg dose is not available
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control. The proportion of patients who maintained pain
control was also evaluated by previous opioid treatment,
sex, and age group (\65 and C65 years of age).
The average weekly pain intensity score (11-point
NRS), change from baseline in average pain intensity, and
percentage change from baseline in pain intensity were
summarized using descriptive statistics. PGIC ratings were
summarized using frequency counts.
The number of doses of rescue medication taken, the
TDD of rescue medication (converted into morphine
equivalent doses using the conversion rate of dosage from
oxycodone to morphine of 1.5), and total number of days
with rescue medication during each week of the treatment
period and during the overall treatment period were sum-
marized using descriptive statistics.
Frequency counts were used to summarize the incidence
of TEAEs, deaths and serious AEs, and AEs leading to
treatment discontinuation. The incidence of TEAEs was
also analyzed by previous opioid treatment, sex, and age
group (\65 and C65 years of age).
In the current study, morphine SR served as a reference
for assay sensitivity, not as an active comparator, so no
formal comparisons of the effectiveness results for ta-
pentadol ER and morphine SR were performed. For that
reason, effectiveness data for the patients in the tapentadol
ER and morphine SR groups are presented separately;
sensitivity analyses (i.e., effectiveness results for morphine
SR) are included in the Electronic Supplementary Material.
Patient disposition and demographic data are presented
together to show that the population analyzed for effec-
tiveness (the tapentadol ER group) was comparable with
the population analyzed for assay sensitivity (the morphine
SR group). Safety and tolerability data for both treatment
groups are presented together to allow for informal com-
parisons of the tolerability of tapentadol ER with that of an




This study was conducted from 23 August 2010 to
17 January 2012. Overall, 100 patients were randomized at
27 sites in Japan and took at least one dose of study drug
(Fig. 1); enrolment was evenly distributed across study
sites. In both the tapentadol ER group and the morphine SR
(reference for assay sensitivity) group, [55 % of patients
completed the treatment period; the most common reasons
Fig. 1 Patient disposition.
ER extended release, SR
sustained release
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for discontinuation were progressive disease (reflecting the
severity of their primary diagnosis of cancer) and AEs
(Fig. 1).
In the tapentadol ER group, 26.0 % (13/50) of patients
had previously taken morphine SR, 44.0 % (22/50) had
previously taken oxycodone CR, and 30.0 % (15/50) had
previously taken transdermal fentanyl. In the morphine SR
(reference for assay sensitivity) group, 24 % (12/50) of
patients had previously taken morphine SR, 46 % (23/50)
of patients had previously taken oxycodone CR, and 30 %
(15/50) of patients had previously taken transdermal fen-
tanyl. Baseline and demographic characteristics for the
tapentadol ER group and the morphine SR (reference for
assay sensitivity) group are summarized in Table 2.
3.2 Tapentadol Extended Release Treatment Exposure
In the tapentadol ER group, the median duration of treat-
ment during the 8-week treatment period was 54.5 days.
The majority [70.0 % (35/50)] of patients in the tapentadol
ER group received study treatment for [28 to B56 days.
The mean (standard deviation [SD]) average TDD of ta-
pentadol ER was 147.2 (91.06) mg during the first week of
study treatment; over the entire 8-week treatment period,
the mean (SD) average TDD of tapentadol ER was 173.5
(101.51) mg. The median modal TDD of tapentadol was
100.0 mg during the first week of treatment and 150.0 mg
over the entire 8-week treatment period. Patients in the
tapentadol ER group took the modal dose for a median of
7.0 days during the first week and a median of 38.0 days
over the entire 8-week treatment period. In the tapentadol
ER group, 28.0 % (14/50) of patients had a dose increase
during the first week of treatment, and 58.0 % (29/50) of
patients had a dose increase over the entire 8-week treat-
ment period (Table 3).
3.3 Effectiveness
For the primary effectiveness endpoint, the percentages of
patients taking tapentadol ER who maintained pain control
(with 95 % CIs) during the first week of treatment overall
and by prior opioid treatment are summarized in Table 4.
Of 50 patients taking tapentadol ER, only eight did not
maintain pain control; two of those patients did not have
pain intensity scores for 3 consecutive days, two failed to
meet the pain intensity criterion, two failed to meet the
rescue medication criterion, and two failed to meet both the
pain intensity and rescue medication criteria. Similar per-
centages of men [80.0 % (20/25)] and women [88.0 % (22/
25)] who were receiving tapentadol ER maintained pain
control during the first week of treatment; the percentage of
patients who maintained pain control was also similar
across the two age groups evaluated [\65 years, 82.6 %
(19/23); C65 years, 85.2 % (23/27)].
The mean (SD) baseline pain intensity score (on prior
opioid treatment; averaged over the 3 days prior to ran-
domization) for patients in the tapentadol ER group was
1.5 (1.11). After switching from previous opioid analgesics
to tapentadol ER, mean average weekly pain intensity
scores were B2 during the entire 8-week treatment period.
Mean changes from baseline in average pain intensity were
B0.4 throughout the treatment period. The mean average
weekly pain intensity score increased to slightly above the
baseline value at Week 1 (mean [SD] change from baseline
to Week 1, 0.4 [0.92]) but thereafter returned progressively





Age, years 66.4 (8.54) 63.8 (9.97)
Age category, n (%)
\65 years 23 (46.0) 25 (50.0)
C65 years 27 (54.0) 25 (50.0)
Sex, n (%)
Male 25 (50.0) 27 (54.0)
Female 25 (50.0) 23 (46.0)
BMI (kg/m2) 19.7 (3.11) 20.3 (3.31)
Baseline pain intensity score 1.5 (1.11) 1.8 (1.14)
Values are expressed as mean (standard deviation) unless otherwise
specified
BMI body mass index, ER extended release, SR sustained release
Table 3 Dose adjustments in the tapentadol extended release group










No change 5 (10.0)





Values are expressed as n (%)
ER extended release
a Missed doses were not considered dose changes
b Percentages were calculated out of the total number of patients
c Percentages were calculated out of the number of patients with dose
decreases or increases
506 K. Imanaka et al.
to the baseline value by Week 8 (mean [SD] change from
baseline to Week 8, 0.0 [0.92]).
PGIC scores at Weeks 1, 4, and 8 are summarized in
Fig. 2. None of the patients taking tapentadol ER reported
a rating of ‘‘very much worse’’ at any timepoint. It is
noteworthy that, although patients experienced adequate
pain control on their previous opioid analgesic (a criterion
for inclusion in the study), there were still some patients
who reported improvements in their overall condition fol-
lowing conversion to tapentadol ER (Fig. 2).
Patients in the tapentadol ER group took rescue medica-
tion for a mean (SD) of 15.9 (19.58) days during the 8-week
treatment period. At baseline (on prior opioid treatment), the
mean (SD) number of doses of rescue medication that
patients in the tapentadol ER group took per day was 0.4
(0.62). The mean (SD) number of doses of rescue medication
taken per day by patients in the tapentadol ER group was
similar to baseline during Week 1 [0.7 (0.99)], Week 4 [0.7
(0.96)], and Week 8 [0.5 (0.76)]. The mean (SD) average
TDD (converted into morphine equivalent doses) of rescue
medication used by patients in the tapentadol ER group
decreased over the course of the treatment period, from 2.9
(8.34) mg during Week 1 to 1.8 (8.27) mg during Week 8;
for the overall treatment period, the mean (SD) average TDD
of rescue medication was 3.0 (8.30) mg.
3.4 Safety and Tolerability
Overall, 90.0 % (45/50) of patients in the tapentadol ER
group and 94.0 % (47/50) of patients in the morphine SR
(reference for assay sensitivity) group reported at least one
TEAE during the 8-week treatment period. The most
common TEAEs (incidence C5 % in either treatment
group) are summarized in Table 5. Disease progression
was the most common TEAE in both treatment groups,
which reflects the disease state of cancer patients who need
opioid analgesics for their pain. The incidence of gastro-
intestinal TEAEs during the 8-week treatment period was
numerically lower in the tapentadol ER group than in the
morphine SR group, particularly the TEAEs of constipation
and vomiting. During Week 1, 42.0 % (21/50) of patients
in the tapentadol ER group and 60.0 % (30/50) of patients
in the morphine SR group reported at least one TEAE.
Gastrointestinal TEAEs were among the most common
TEAEs reported during Week 1; in the tapentadol ER
and morphine SR groups, respectively, 4.0 % (2/50) and
14.0 % (7/50) of patients reported nausea, 2.0 % (1/50)
and 16.0 % (8/50) reported vomiting, and 2.0 % (1/50) and
14.0 % (7/50) reported constipation.
In the tapentadol ER group, at least one TEAE was
reported during the 8-week treatment period by 84.6 %
(11/13) of patients who previously took morphine SR,
95.5 % (21/22) of patients who previously took oxycodone
CR, and 86.7 % (13/15) of patients who previously took
transdermal fentanyl. In the morphine SR group, at least


















































Fig. 2 Patient Global Impression of Change ratings at Weeks 1, 4,
and 8 for patients taking tapentadol extended release (full analysis
population). None of the patients reported a rating of ‘‘very much
worse’’ at Week 1, 4, or 8











Patients achieving pain control, n (%) 42 (84.0) 9 (69.2) 20 (90.9) 13 (86.7)
95 % CI 70.89–92.83 38.57–90.91 70.84–98.88 59.54–98.34
CI confidence interval, CR controlled release, ER extended release, SR sustained release
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75.0 % (9/12) of patients who previously took morphine SR,
100.0 % (23/23) of patients who previously took oxycodone
CR, and 100.0 % (15/15) of patients who previously took
transdermal fentanyl. The overall incidence of TEAEs was
similar for male and female patients in the tapentadol ER
group [92.0 % (23/25) vs. 88.0 % (22/25)] and in the mor-
phine SR group [96.3 % (26/27) vs. 91.3 % (21/23)]. For
patients\65 and C65 years of age, respectively, the overall
incidences of TEAEs were 95.7 % (22/23) and 85.2 % (23/
27) in the tapentadol ER group and 96.0 % (24/25) and
92.0 % (23/25) in the morphine SR group.
Drug-related TEAEs were less common with tapent-
adol ER [38.0 % (19/50)] than with morphine SR [64.0 %
(32/50)], as were TEAEs leading to treatment discontin-
uation [28.0 % (14/50) vs. 38.0 % (19/50)]. The most
common TEAEs leading to treatment discontinuation
(incidence [2 % in either treatment group) were disease
progression [tapentadol ER, 18.0 % (9/50); morphine SR,
22.0 % (11/50)] and vomiting [tapentadol ER, 0;
morphine SR, 8.0 % (4/50)].
Overall, 32.0 % (16/50) of patients in the tapentadol ER
group and 32.0 % (16/50) of patients in the morphine SR
group had a serious TEAE. There were six deaths in the
tapentadol ER group; five of these deaths were due to
disease progression and were considered by the investiga-
tor to be unrelated to study drug, and one was due to
gastrointestinal perforation that occurred 30 days after
starting tapentadol ER and was considered by the investi-
gator to be doubtfully related to study drug. There were
four deaths in the morphine SR group, all of which were
due to disease progression and were considered by the
investigator to be unrelated to study drug.
In the tapentadol ER group, there were no unexpected
safety results attributable to treatment based on laboratory,
vital sign, and ECG values.
4 Discussion
Results of this study showed that conversion from opioid
analgesics (morphine SR, oxycodone CR, or transdermal
fentanyl) to tapentadol ER was successful in patients with
moderate to severe, chronic malignant tumor–related pain
that was well-controlled on their previous opioid; pain
control was maintained after switching to tapentadol ER
treatment and tapentadol ER was generally well-tolerated.
This study design did not follow the switching criteria
typically used in clinical practice, which generally involves
switching opioid analgesics only for patients who experi-
ence inadequate pain control or intolerable side effects on
their current opioid. The intention of the current study was
to show under controlled experimental conditions that
patients with stable pain control could achieve comparable
effectiveness with tapentadol ER, in order to be able to
recommend this switch as necessary in practice. Pain
control was maintained by 84 % of patients within the first
week after switching to tapentadol ER. For the primary
effectiveness endpoint, a 7-day period after switching from
the previous strong opioid analgesic was considered suffi-
cient to demonstrate pain control because the initial dose of
study drug was based on the dose of the previous opioid,
which had provided adequate pain control [as indicated by
a pain intensity (NRS) score \4]. Although pain control
was consistent following direct conversion from prior
opioid therapy to tapentadol ER, effectiveness in the ta-
pentadol ER group further improved over time after
Week 1; this further improvement indicates that the best
effectiveness was obtained after the initial conversion
when patients were individually titrated to their optimal
dose, balancing effectiveness and tolerability. The sensi-
tivity of effectiveness analyses in the current study were
Table 5 Incidence of treatment-emergent adverse events reported by









General disorders and administration-site
conditions
21 (42.0) 20 (40.0)
Disease progression 16 (32.0) 17 (34.0)
Malaise 4 (8.0) 0
Pyrexia 3 (6.0) 4 (8.0)
Nervous system disorders 18 (36.0) 17 (34.0)
Somnolence 8 (16.0) 10 (20.0)
Headache 1 (2.0) 4 (8.0)
Gastrointestinal disorders 19 (38.0) 27 (54.0)
Nausea 7 (14.0) 7 (14.0)
Constipation 6 (12.0) 10 (20.0)
Vomiting 3 (6.0) 13 (26.0)
Diarrhea 3 (6.0) 4 (8.0)
Blood and lymphatic system disorders 8 (16.0) 3 (6.0)
Anemia 4 (8.0) 1 (2.0)
Psychiatric disorders 5 (10.0) 1 (2.0)
Insomnia 4 (8.0) 0
Injury, poisoning, and procedural
complications
4 (8.0) 4 (8.0)
Fall 4 (8.0) 1 (2.0)
Investigations 8 (16.0) 13 (26.0)
c-Glutamyltransferase increased 1 (2.0) 4 (8.0)
Skin and subcutaneous tissue disorders 8 (16.0) 10 (20.0)
Pruritus 1 (2.0) 4 (8.0)
Values are expressed as n (%)
ER extended release, SR sustained release, TEAE treatment-emergent
adverse event
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validated based on the positive results achieved with mor-
phine SR; a high percentage of patients (98 %) maintained
pain control during the first week with morphine SR. Mor-
phine SR was chosen as the reference for assay sensitivity in
this study because it is generally considered to be the stan-
dard of care for the management of moderate to severe
cancer pain requiring a strong opioid and has been used
extensively in cancer pain studies [30]. Because this study
included patients who were previously on strong opioid
analgesics (including morphine SR), some patients who
were previously taking morphine SR would have been ran-
domized to the same treatment (morphine SR) during open-
label treatment, which may have introduced bias in favor of
the morphine SR group; in fact, 24 % of patients in the
morphine SR group were pretreated with morphine SR prior
to conversion. For that reason, direct comparisons of
effectiveness between the tapentadol ER group, in which all
patients had previously received other strong opioids (mor-
phine SR, oxycodone CR, or transdermal fentanyl), and the
morphine SR treatment group may not have yielded accurate
results for interpretation of conversion in this group.
PGIC outcomes supported the results of the primary
effectiveness analysis in the tapentadol ER group; the
percentage of patients reporting an improvement or no
change in their overall condition on the PGIC increased
over the course of the 8-week treatment period. Only
patients with adequate pain control on their previous opioid
analgesic were included in this study, so major improve-
ments were not expected in patients’ overall condition.
With tapentadol ER, the majority of patients experienced
no change or a minimal improvement; this is consistent
with the inclusion of a population with well-controlled pain
on their previous analgesic regimen, but also suggests that
the majority of patients treated with tapentadol ER either
maintained or experienced improvements in their pain
control and overall condition.
In the current study, tapentadol ER was generally well-
tolerated and there were no unexpected safety findings. The
incidence of gastrointestinal TEAEs (particularly vomiting
and constipation), drug-related AEs, and AEs leading to
discontinuation was lower with tapentadol ER than with
morphine SR. Additionally, the differences observed in this
study between tapentadol ER and morphine SR in gastro-
intestinal tolerability and in AEs leading to discontinuation
were comparable with differences seen between tapentadol
and oxycodone in other phase III studies in acute and
chronic pain [13, 14, 31–33]. The improvement in gastro-
intestinal side effects with tapentadol ER may be of par-
ticular clinical relevance because gastrointestinal side
effects often lead patients to discontinue therapy, resulting
in disruption of pain relief [34, 35].
The conversion ratio used in the current study to deter-
mine starting doses of tapentadol ER and morphine SR was
based on prior estimates of the equianalgesic ratio of ta-
pentadol ER to oxycodone CR (*5:1) [21, 22] and of the
equianalgesic ratio between oxycodone CR, morphine SR,
and a fentanyl transdermal system (2:3:0.03) [23–26]. The
tapentadol ER to morphine SR conversion ratio in the current
study (3.3:1) was in keeping with previously reported esti-
mates [17, 21]. There is generally a range of estimates of dose
conversion ratios for opioid analgesics [6, 36], and the con-
version ratios used in the current study were at the lower end
of those ranges. This type of conservative approach may be
associated with a better response to opioid treatment and a
more favorable tolerability profile than a more aggressive
treatment strategy [6, 36].
The daily doses of tapentadol ER used in the current
study were relatively low. For tapentadol ER, the mean
average TDD used in the current study was 173.5 mg; by
comparison, the mean average TDD of tapentadol ER used
in previous studies in patients with chronic osteoarthritis or
low back pain ranged from 232.7 to 326.7 mg [13, 14, 21,
22, 31, 37]. The difference in TDDs between the current
study and those previous studies may have been related to
differences in study populations. The previous studies
included largely North American and European patients
[13, 14, 21, 22, 31, 37], while the current study included
exclusively Japanese patients. In general, Japanese patients
require lower doses of opioid-type analgesics to control
their cancer pain than Western patients [18, 38–40].
This study may be associated with some inherent limi-
tations, including the fact that the study is not double-blind.
The open-label design of this first conversion study with
tapentadol ER in Japanese patients was intended to ensure
the safety of study participants and to allow proper dosing
decisions to be made for these patients. In addition, some
patients randomized to treatment in the morphine SR group
had previously been taking morphine SR; results for those
patients, who received continuous treatment with a single
opioid may have differed from results for patients who
switched from a different previous opioid to morphine SR
or tapentadol ER. The positive results achieved in the
current study, which showed that tapentadol ER was safe
and effective for chronic cancer pain management after
direct conversion from WHO Step III opioids, were con-
gruous with those of previous studies showing safe and
effective pain relief with tapentadol ER after direct con-
version from WHO Step III opioids in patients with dif-
ferent types of chronic pain [21, 22].
Overall, results of this study indicate that patients whose
moderate to severe, cancer-related pain was previously
well-controlled with morphine SR, oxycodone CR, or
transdermal fentanyl were safely converted to tapentadol
ER (50–250 mg twice daily) with no loss of pain control.
The majority of patients had maintained pain control within
1 week of conversion to tapentadol ER, indicating that direct
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conversion from prior strong opioid therapy to tapentadol
ER was successful. In addition, tapentadol ER had a better
gastrointestinal tolerability profile than morphine SR; a
notable difference in the incidence of gastrointestinal AEs
between tapentadol ER and morphine SR was observed after
only 1 week of treatment. The favorable tolerability profile
of tapentadol ER may improve compliance in patients with
chronic cancer-related pain, resulting in more consistent
pain relief and better patient outcomes.
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